Autolus Therapeutics plc (NASDAQ:AUTL – Get Free Report) was the target of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 11,900,000 shares, a growth of 74.7% from the June 30th total of 6,810,000 shares. Based on an average trading volume of 1,710,000 shares, the days-to-cover ratio is presently 7.0 days.
Institutional Trading of Autolus Therapeutics
Several institutional investors have recently added to or reduced their stakes in the company. EWA LLC boosted its stake in Autolus Therapeutics by 40.2% in the 4th quarter. EWA LLC now owns 25,678 shares of the company’s stock valued at $155,000 after purchasing an additional 7,361 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Autolus Therapeutics by 66.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 27,034 shares of the company’s stock valued at $172,000 after acquiring an additional 10,771 shares during the period. EntryPoint Capital LLC lifted its position in shares of Autolus Therapeutics by 113.6% during the 1st quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock valued at $137,000 after acquiring an additional 11,456 shares during the period. Privium Fund Management B.V. lifted its position in shares of Autolus Therapeutics by 43.2% during the 1st quarter. Privium Fund Management B.V. now owns 50,058 shares of the company’s stock valued at $319,000 after acquiring an additional 15,091 shares during the period. Finally, Bayesian Capital Management LP bought a new stake in shares of Autolus Therapeutics during the 1st quarter valued at $100,000. 72.83% of the stock is currently owned by institutional investors.
Autolus Therapeutics Price Performance
AUTL traded up $0.07 during trading on Friday, hitting $4.67. The stock had a trading volume of 626,708 shares, compared to its average volume of 1,411,487. The company has a 50 day moving average price of $4.02 and a 200-day moving average price of $5.08. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -3.89 and a beta of 2.11. Autolus Therapeutics has a one year low of $2.01 and a one year high of $7.45.
Analyst Ratings Changes
A number of research analysts recently weighed in on the company. Truist Financial boosted their target price on Autolus Therapeutics from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, April 9th. William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a report on Monday, June 3rd. Finally, Needham & Company LLC reissued a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a report on Monday, June 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Autolus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $8.70.
Read Our Latest Stock Report on Autolus Therapeutics
Autolus Therapeutics Company Profile
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
See Also
- Five stocks we like better than Autolus Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Why Call Options Volume for These 2 Stocks Spiked Together
- What Makes a Stock a Good Dividend Stock?
- MarketBeat Week in Review – 7/22 – 7/26
- Which Wall Street Analysts are the Most Accurate?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.